Clinical trials: Type 2 Diabetic Patients
Type 2 Diabetes Mellitus
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
The purpose of this study is to evaluate benefits and risks of lixisenatide (AVE0010), in comparison to sitagliptin, as an add-on treatment to metformin, in obese (body mass index [BMI] greater than or equal to 30 kilogram per…
- Trial name
- NCT00976937
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sitagliptin
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 319 people
- Sponsor
- Sanofi
Covid19
AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19
The ARCADIA Trial is a randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with either Type 1 or Type 2 diabetes, hospitalised with COVID-19.
- Trial name
- ARCADIA (NCT04516759)
- Testing
- AZD1656
- Where
- 30 sites in Czechia, Romania and 1 more
- Volunteers
- 170 people
- Sponsor
- St George Street Capital
Type 2 Diabetic Patients
Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk
Study to investigate microvascular and antiinflammatory effects of Rivaroxaban compared to low dose aspirin in type 2 diabetic patients.
- Trial name
- MicroVasc-DIVA (NCT02164578)
- Testing
- Rivaroxaban, Aspirin
- Where
- 5 sites in Germany
- Volunteers
- 179 people
- Sponsor
- GWT-TUD GmbH
Diabetic Neuropathy
Alpha Lipoic Acid for Treatment of Diabetic Neuropathy
Patients with diabetic neuropathy and total symptoms score(TSS) >7 points were invited to this open multicenter study. Patients were free of pain medications and severe diabetic complications .Patients started alpha lipoic acid…
- Trial name
- NCT02439879
- Testing
- Alpha lipoic acid
- Volunteers
- 45 people
- Sponsor
- Universidad Popular Autónoma del Estado de Puebla
Hypertension, Diabetes Mellitus, Type II
Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control
This is a 24-week, prospective, multicenter, open-label, single-arm study to assess the effect of bisoprolol on glycemic level in Type 2 diabetes mellitus (T2DM) controlled subjects with hypertension.
- Trial name
- GIANT (NCT01066039)
- Testing
- Bisoprolol
- Where
- South Korea
- Volunteers
- 202 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Carotid Artery Disease, Carotid Artery Stenosis
Effect of Raised CBF During CEA on Cognition in DM Patients
The purpose of this study is to determine if we can reduce the incidence of cognitive dysfunction - difficulty in performing certain pencil-paper, memory, finger dexterity and thinking type of tasks called neuropsychometric tests…
- Conditions
- Carotid Artery Disease, Carotid Artery Stenosis, Diabetes, Cognitive Dysfunction
- Trial name
- NCT00597545
- Testing
- Carotid endarterectomy, Shunt
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
Hepatitis C, Chronic, DIABETES MELLITUS Type 2
The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients
The purpose of this study is to investigate if nitazoxanide used in combination with interferon alfa and ribavirin is effective in treating Hepatitis c infected type 2 Diabetic patients by improving their sustained viral response…
- Trial name
- HEP-C-FM (NCT01770483)
- Testing
- nitazoxanide, conventional interferon alfa, Ribavirin
- Where
- Pakistan
- Volunteers
- 66 people
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Diabetes Mellitus, Type II
Multifactorial Treatment of Cardiovascular Risk in Diabetic Patients: Identification of Treatment Non-Responders
The aim of the study is to develop a model that allows early identification of type-2 diabetic patients who will face progressive atherosclerosis despite intensive, multifactorial, target oriented treatment
- Trial name
- CARDIONOR (NCT00660790)
- Testing
- Intensified Treatment of risk factors
- Where
- Austria
- Volunteers
- 97 people
- Sponsor
- Medical University of Graz
Diabetic Nephropathy
Effect of Sulodexide in Early Diabetic Nephropathy
The purpose of the study is to determine whether treatment with sulodexide is effective in reducing the level of urine albumin excretion in patients with early diabetic kidney disease expressed as microalbuminuria.
- Trial name
- NCT00130208
- Testing
- Sulodexide
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 1,056 people
- Sponsor
- Keryx Biopharmaceuticals
Type 2 Diabetes
A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes
- Trial name
- NCT00374907
- Testing
- Saxagliptin, Metformin (blinded), Metformin (open-label)
- Where
- 3 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Hypertension, Type 2 Diabetes Mellitus
Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients
This study will evaluate the effects of nebivolol on glycemic control compared with metoprolol and HCTZ in patients with hypertension and type 2 diabetes mellitus
- Trial name
- NCT00744237
- Testing
- Nebivolol, Metoprolol ER, HCTZ
- Where
- 65 sites in United States, Puerto Rico
- Volunteers
- 231 people
- Sponsor
- Forest Laboratories
Type 2 Diabetes Mellitus, Colonoscopy
Abnormal Blood Sugar Tests in Diabetic Patients During Colonoscopy Preparation
Type 2 diabetes is rapidly increasing globally and has been associated with an increased risk of colorectal cancer. Therefore, the numbers of diabetic patients who will undergo colonoscopic screening are expected to grow…
- Trial name
- NCT03109951
- Testing
- Colonoscopy preparation using polyethylene glycol
- Where
- South Korea
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Catholic Kwandong University
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment in monotherapy in patients with…
- Trial name
- NCT01214239
- Testing
- Linagliptin
- Where
- 19 sites in China, Malaysia and 1 more
- Volunteers
- 300 people
- Sponsor
- Boehringer Ingelheim
Diabetic Retinopathy
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
- Trial name
- NCT00604383
- Testing
- ruboxistaurin
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Chromaderm, Inc.
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor.
- Trial name
- NCT02010242
- Testing
- GKT137831
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 136 people
- Sponsor
- Calliditas Therapeutics AB
Type 2 Diabetes
How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics
This study is designed to look at how using glargine insulin with oral diabetes medications and exenatide may improve control of blood sugar levels and weight gain in type 2 diabetics. The main study will last 32 weeks.
- Trial name
- MEXELIN (NCT00667732)
- Testing
- exenatide
- Where
- 3 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Diabetes, Type I, Diabetes, Type II
Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Coronary vascular dysfunction is highly prevalent among patients with known or suspected Coronary Artery Disease (CAD)1, increases the severity of inducible myocardial ischemia (beyond the effects of upstream coronary…
- Conditions
- Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease
- Trial name
- RAND-CFR (NCT01754259)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Brigham and Women's Hospital
Painful Diabetic Neuropathy
Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)
The purpose of this study is to evaluate safety and efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN).
- Trial name
- EMPADINE (NCT03297294)
- Testing
- EMA401
- Where
- 64 sites in Australia, Austria and 14 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
The objective of the current study is to investigate the efficacy, safety and tolerability of Linagliptin (5 mg once daily) compared to placebo given for 24 weeks as add on therapy to metformin in combination with pioglitazone in…
- Trial name
- NCT00996658
- Testing
- Linagliptin
- Where
- 52 sites in United States, France and 2 more
- Volunteers
- 278 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients
This is a phase 3 trial designed to compare the effects of twice daily exenatide plus oral antidiabetic agents (OADs) and once-daily insulin glargine plus OADs with respect to glycemic control, as measured by hemoglobin A1c, with…
- Trial name
- NCT00360334
- Testing
- exenatide, insulin glargine
- Where
- 31 sites in United Kingdom
- Volunteers
- 235 people
- Sponsor
- AstraZeneca